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Hypertrophic scar is a complication of wound healing and has a high recurrence rate which can lead to significant abnormity
in aesthetics and functions. To date, no ideal treatment method has been established. Meanwhile, the underlying mechanism
of hypertrophic scarring has not been clearly defined. Although a large amount of scientific research has been reported on the
use of medicinal plants as a natural source of treatment for hypertrophic scarring, it is currently scattered across a wide range of
publications. Therefore, a systematic summary and knowledge for future prospects are necessary to facilitate further medicinal
plant research for their potential use as antihypertrophic scar agents. A bibliographic investigation was accomplished by focusing
on medicinal plants which have been scientifically tested in vitro and/or in vivo and proved as potential agents for the treatment
of hypertrophic scars. Although the chemical components and mechanisms of action of medicinal plants with antihypertrophic
scarring potential have been investigated, many others remain unknown. More investigations and clinical trials are necessary to
make use of these medical plants reasonably and phytotherapy is a promising therapeutic approach against hypertrophic scars.
1. Introduction
Scar formation strongly depends on the presence of contrac-
tion during healing and the nature of the scar is actually
the uneven look of the healed tissue resulting from disfig-
ured tissue deformation and overaligned collagen fibers [1].
Collagen in hypertrophic scars is found to be in a disor-
ganized, whorl-like arrangement rather than in the normal
parallel orientationmanner.Therefore, hypertrophic scars are
indurate, elevated, poorly extensible, and also characterized
by hypervascularity, thereby providing their erythematous
appearances [2]. HS can cause significant abnormality in
aesthetic and functional symptoms and to date no recognized
treatment has been established. It commonly occurs after
surgical incision, thermal injury, and traumatic injuries to
the dermis with a subsequent abnormal healing response
[3]. Furthermore, it is often associated with contractures that
can lead to considerably reduced functional performance in
patients.
The development of antihypertrophic scars is an unsolved
problem in the process of scar treatment. For this rea-
son, some undiscovered successful treatments are needed
to prevent excessive hypertrophic scarring. The reported
preventions include topical medical application, cryotherapy,
use of silicone gel sheets, injection of steroids, radiotherapy,
and an early surgical procedure for wound closure [2]. In the
last decade, there has been a renewed interest in the use of
indigenous medicine worldwide, arising from the realization
that orthodoxmedicine is not widespread. Althoughmodern
medicine may be available in some communities, herbal
medicines have often maintained popularity for historical
and cultural reasons, in addition to their cheaper costs [4].
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Figure 1: The mechanism of hypertrophic scarring.
Recent research has introduced the uses of phytochemical
compounds and extracts isolated frommedicinal plants in an
attempt to resolve these problems as a promising therapy.
Many treatment strategies are sought to prevent scar
formation without compromising the wound healing process
[5].The effectiveness of currently used therapy against hyper-
trophic scar arises most probably from the increase of the
medicinal plants reported. In themodern systemofmedicine,
about 25%of prescriptions contain active principle(s) derived
from plants [4]. A significant correlation between medicinal
plants and their use in the treatment of many types of
scars has been shown in epidemiological data generated
throughout the world. Published clinical trials have, as
yet, largely focused on characterizing the pharmacokinetics
and metabolism of medicinal plants. Despite experimental
advances in medicinal plant research against scars, findings
in humans are still limited. However, in recent years, diverse
benefits of medicinal plants in the treatment of hypertrophic
scars have been described [6–9].
In line with the latest findings responsible for the
increased recognition of medicinal plants as potential ther-
apeutic and/or preventative agents, the aim of the present
review is to focus on recent experimental findings and
clinical trials of medicinal plants and other preparations with
similar actions that could account for beneficial effects on
hypertrophic scars in patients. Natural products, such as
plant extracts, either as pure compounds or as standard-
ized extracts, provide unlimited opportunities for control of
hypertrophic scarring owing to their chemical diversity [10].
Currently, a great deal of effort is being expended to find
alternative sources of safe, effective, and acceptable natural
medicinal plants for the treatment or prevention of hyper-
trophic scars; hence, all literature available was reviewed.
2. Suggested Mechanism of
Hypertrophic Scarring
The molecular mechanism of hypertrophic scarring is asso-
ciated with the unusual proliferation of fibroblasts and over-
production of collagen and extracellularmatrix [70]. An array
of intra- and extracellular mechanisms is essential in the pre-
vention of scar formation.With the help ofmolecular biology,
cell biology technology, hypertrophic scar animal models,
and the setting-up of scar tissue engineering, the mechanism
of hypertrophic scarring has been clearly defined (Figure 1).
It is usually considered as migration and proliferation of
different cell types such as keratinocytes, myofibroblasts [59],
and mast cells [71]. Fibroblasts play an essential role in new
tissue formation during wound repair [33], but their abnor-
mal low death rate and high proliferation rate can cause scar
tissue formulation [11]. Meanwhile, keratinocytes are indis-
pensable in signal transduction between paracrine secretion
and epitheliummatrix.When cultured in the presence of ker-
atinocytes, fibroblasts exhibit significant proliferation activity
[72], showing the contribution of keratinocytes to fibrob-
lasts proliferation. Myofibroblasts, which are different from
fibroblasts and are related to the composition, organization,
and mechanical properties of ECM [73], increase collagen
synthesis and retard cell migration [71], thus resulting in
excessive and rigid scarring. Fibroblasts are transformed into
myofibroblasts by heterocellular gap junction intercellular
communications between mast cells (RMC-1) and fibroblasts
[71, 74]. In the process of wound healing, the combination
of fibroblasts and myofibroblasts triggers excessive produc-
tion of abnormal extracellular matrix protein [75], eliciting
scarring [1, 75].With the assistance of keratinocytes andmast
cells, proliferative fibroblasts producemassive collagenwhich
makes extracellular matrix accumulate below dermis, leading
to scar formation. The complex forming process consists
of three different phases, inflammation, proliferation, and
maturation, which leads to hypertrophic scarring in the end
[76]. The ratio of I to III collagens in healthy adults ranges
from 3.5 to 6.1, while in patients with hypertrophic scars,
it could be down to 2 and in keloid patients it can be as
high as 19, which is related to the abnormal metabolism
of collagens I and III in pathological scars, including more
collagen synthesis and less collagen degradation.
Although many targets of action, by which scarring can
be inhibited, have been experimentally studied or postulated,
few are well known or defined for inhibition of hypertrophic
scarring by plant-derived compounds. Figure 2 and Tables 5
and 6 summarize and enumerate the suggested mechanisms
and correlative medicinal plants.
The size of a scar is influenced by many factors, such as
wound size, wound contraction, and healing time. Wound
contraction makes an important contribution to scar for-
mation also the larger the area of the wound, the more
cells migrate, resulting in more prominent scarring [1].
Therefore, induction of fibroblast apoptosis and reduction of
extracellular matrix and collagen I/III production may be the
pivotal measures against hypertrophic scarring.
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Figure 2: The mechanisms by which extracts and compounds from medicinal plants display antihypertrophic scar activity.
Many kinds of test models are applied to investigate
wound healingmechanisms and inhibition of scar formation,
including 2D hybrid agent-based model [1], pig surgical
injury model, fibroblast populated collagen lattice (FPCL)
model, rat laminectomies at Lumbar-1 level [5], incisional
wound healing model [6], and rabbit ear model [54]. These
models provide a mean for detecting and evaluating the
mechanobiology in wound healing and scar formation [1].
However, the complex mechanism of hypertrophic scar-
ring still remains unknown which raises the question of how
to control scar hyperplasia.
3. Medicinal Plants against
Hypertrophic Scarring
Many beneficial uses of medicinal plants are extensively
documented in the traditionalmedicine systems inmany cul-
tures. To collect the data which supports this finding, we per-
formed a systematic review using PubMed, Elsevier, Springer,
and Google Scholar databases and peer-reviewed articles
published in the last 10 years. The search terms included
scar, scaring, fibroblast, extract, and preparation. The phyto-
chemicals from medicinal plants against scar hyperplasia are
presented in Tables 1 and 2, respectively, whilst the medicinal
plant extracts are listed in Table 3. Their activities and mech-
anisms for antihypertrophic scarring were also described,
respectively, in Tables 1, 2, and 3. There are five prepara-
tions (Table 4) reported on their effects and mechanisms
of antihypertrophic scarring, namely, liposome-encapsulated
10-HCPT, oxymatrine-phospholipid complex (OMT-PLC),
solid lipid nanoparticle-enriched hydrogel (SLN-gel), Gin-
senoside Rg3/poly (l-lactide) (G-Rg3/PLLA), and Centella
asiatica extract capsule, which are composed of different
medicinal plants and vehicles. Medicinal plants can be used
for different therapeutic purposes or as precursors of useful
drugs containing different types of phytochemicals.
The use of herbal medicine remedy has been steadily
increasing worldwide in recent years, as well as the search
for new phytochemicals that could be potentially developed
as useful drugs for the treatment of hypertrophic scar and
other scar diseases [4]. The antihypertrophic scar activity
of medicinal plants results from a variety of components
contained in these plants (Tables 1 and 2).Many plant extracts
(Table 3) have antihypertrophic scar activity owing to their
phytochemical constituents. However, more work is needed
to focus on purification and identification of active compo-
nents and to elucidate the roles that these play in inhibition
of scars when used alone or jointly. Moreover, many of them
have not been tested for their cytotoxicity to normal cells,
which seriously blocks in vivo investigations. Undeniably,
no toxic and side effects have been proved for some active
components. For example, Genistein, which is easily obtained
and commonly used for hypertrophic scar treatment, has
strong pharmacological effects, with no obvious toxicity or
side effects [13].
4. New Preparations of Medicinal Plants
A large number of extracts and compounds of medicinal
plants display antiscar activity. Nevertheless, drugs are diffi-
cult to get through the stratum corneum due to the natural
barrier of skin, which causes lower permeability of drugs.
The oral bioavailability of drugs at the permissive dose is
very low, owing to their hydrophilicity (low permeability),
4 Evidence-Based Complementary and Alternative Medicine
Ta
bl
e
1:
Th
ec
om
po
ne
nt
sf
ro
m
m
ed
ic
in
al
pl
an
ts
w
ith
an
tih
yp
er
tro
ph
ic
sc
ar
ac
tiv
ity
.
C
om
po
ne
nt
Bo
ta
ni
ca
l
na
m
e
Fa
m
ily
M
ed
ic
in
al
pa
rt
O
bs
er
va
tio
n
D
os
e
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
M
ad
ec
as
so
sid
e
Ce
nt
ell
a
as
ia
tic
a
U
m
be
lli
fe
ra
e
W
ho
le
pl
an
t
In
vi
tro
10
∼
10
0𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
Pr
om
ot
io
n
of
ap
op
to
sis
D
im
in
ish
m
en
to
fs
ca
rf
or
m
at
io
n
Fa
ci
lit
at
io
n
of
wo
un
d
he
al
in
g
In
hi
bi
tio
n
of
H
KF
m
ig
ra
tio
n,
F-
ac
tin
fil
am
en
ts
pr
ot
ei
n,
an
d
cy
to
sk
ele
ta
l
pr
ot
ei
n.
Pr
om
ot
io
n
of
nu
cle
ar
sh
rin
ka
ge
an
d
m
ito
ch
on
dr
ia
lm
em
br
an
e
de
po
la
riz
at
io
n
C
on
de
ns
at
io
n
of
ch
ro
m
at
in
an
d
fr
ag
m
en
to
fn
uc
lei
In
hi
bi
to
ry
ph
os
ph
or
yl
at
io
n
of
p3
8,
PI
3K
,
A
KT
,a
nd
co
fil
in
.A
ct
iv
at
io
n
of
ca
sp
as
e-
3/
ca
sp
as
e-
9
Fa
ci
lit
at
io
n
of
Ba
x
m
RN
A
ex
pr
es
sio
n
an
d
de
cr
ea
se
of
Bc
l-2
an
d
M
M
P-
13
m
RN
A
ex
pr
es
sio
n
[1
1,
12
]
G
en
ist
ei
n
Gl
yc
in
em
ax
Le
gu
m
in
os
ae
Fr
ui
t
In
vi
tro
25
∼
10
0𝜇
g/
m
L
A
nt
i-p
ro
lif
er
at
io
n
of
H
SF
Bs
Su
pp
re
ss
io
n
of
m
ito
sis
Pr
om
ot
io
n
of
ap
op
to
sis
In
hi
bi
tio
n
of
TP
Ks
,i
nc
re
as
eo
fc
as
pa
se
-3
,
an
d
de
cr
ea
se
so
f𝛼
-S
M
A
an
d
Bc
l-2
pr
ot
ei
n
En
ha
nc
em
en
to
fB
ax
pr
ot
ei
n
In
hi
bi
tio
n
of
ty
pe
sI
/II
Ip
re
co
lla
ge
n
m
RN
A
ex
pr
es
sio
n,
do
w
n-
re
gu
lat
io
n
of
co
lla
ge
n
I/I
II
m
RN
A
,r
ed
uc
tio
n
of
PC
N
A
ex
pr
es
sio
n,
an
d
in
hi
bi
to
ry
ph
os
ph
or
yl
at
io
n
of
c-
Ra
f,
M
EK
1/2
,
ER
K1
/2
,a
nd
p3
8
In
du
ct
io
n
of
m
or
ph
ol
og
y
ch
an
ge
so
fa
po
pt
os
is
ce
lls
In
hi
bi
to
ry
tr
an
sd
iff
er
en
tia
tio
n
of
fib
ro
bl
as
ts
in
to
m
yo
fib
ro
bl
as
ts
[1
3–
17
]
37
∼
37
0𝜇
M
D
ec
re
as
eo
fG
0-
G
1
ph
as
ea
nd
in
cr
ea
se
of
G
2-
M
ph
as
eI
nc
re
as
eo
fC
-J
U
N
m
RN
A
ex
pr
es
sio
n
an
d
de
cr
ea
se
of
FO
S-
B
m
RN
A
ex
pr
es
sio
n
in
sk
in
ke
ra
tin
oc
yt
es
In
hi
bi
to
ry
m
RN
A
ex
pr
es
sio
n
of
C-
JU
N
an
d
C-
FO
S
in
hu
m
an
fib
ro
bl
as
ts
In
ke
lo
id
fib
ro
bl
as
ts,
de
cr
ea
se
of
C-
JU
N
an
d
C-
FO
S
m
RN
A
ex
pr
es
sio
n
at
37
𝜇
M
,b
ut
en
ha
nc
em
en
ta
t3
70
𝜇
M
As
tr
ag
al
os
id
e
IV
As
tra
ga
lu
s
M
em
-
br
an
ac
eu
s
Le
gu
m
in
os
ae
Ro
ot
In
vi
tro
12
.5
∼
20
0𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
D
ec
re
as
eo
fc
ol
la
ge
n
I/c
ol
la
ge
n
II
Ia
nd
TG
F-
𝛽
1
se
cr
et
io
n
[1
8]
Evidence-Based Complementary and Alternative Medicine 5
Ta
bl
e
1:
C
on
tin
ue
d.
C
om
po
ne
nt
Bo
ta
ni
ca
l
na
m
e
Fa
m
ily
M
ed
ic
in
al
pa
rt
O
bs
er
va
tio
n
D
os
e
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
Te
tr
an
dr
in
e
St
ep
ha
ni
a
te
tra
nd
ra
M
en
isp
er
m
ac
ea
e
Ro
ot
In
vi
tro
10
∼
80
𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
TG
F-
𝛽
1
m
RN
A
tr
an
sc
rip
tio
n,
pr
om
ot
io
n
of
Sm
ad
7
an
d
M
M
P-
1m
RN
A
ex
pr
es
sio
n,
an
d
in
hi
bi
tio
n
of
Sm
ad
2
m
RN
A
ex
pr
es
sio
n
D
ec
re
as
eo
f
pr
ot
ei
n
ex
pr
es
sio
n
of
co
lla
ge
n
I/c
ol
la
ge
n
II
I,
Bc
l-2
,a
nd
M
KP
-1
.R
ed
uc
tio
n
of
to
ta
l
co
lla
ge
n
vo
lu
m
ea
nd
S
ph
as
e,
in
cr
ea
se
of
G
0/
G
1
ph
as
e,
an
d
pr
ev
en
tio
n
of
G
0/
G
1
in
to
G
2
ph
as
eI
nh
ib
ito
ry
ph
os
ph
or
yl
at
io
n
of
M
EK
1/2
an
d
ER
K1
/2
[19
–2
2]
In
vi
vo
1∼
10
m
g/
L
Lo
ca
l
in
je
ct
io
n
0.
5∼
2m
g/
L
50
m
g/
m
L,
20
𝜇
L
A
lo
e-
em
od
in
Rh
eu
m
pa
lm
at
um
Po
lyg
on
ac
ea
e
Ro
ot
,
rh
iz
om
e
In
vi
tro
20
∼
80
m
g/
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
cr
ea
se
of
S
ph
as
e
[2
3]
5F
Pt
er
is
se
m
ip
in
na
ta
Pt
er
id
ac
ea
e
W
ho
le
pl
an
t
In
vi
tro
20
∼
80
𝜇
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
PS
Bl
oc
ka
ge
of
fib
ro
bl
as
ts
fro
m
G
1
to
S
ph
as
e
D
ec
re
as
ed
pr
ot
ei
n
ex
pr
es
sio
n
of
TG
F-
𝛽
1
an
d
ty
pe
Ic
ol
la
ge
n,
in
cr
ea
se
of
ca
sp
as
e-
3,
an
d
re
du
ct
io
n
of
to
ta
lc
ol
la
ge
n
an
d
fib
ro
bl
as
ts
PC
N
A
pr
ot
ei
n
(c
yc
lin
)
In
hi
bi
to
ry
m
RN
A
ex
pr
es
sio
n
of
ty
pe
I/t
yp
eI
II
pr
oc
ol
la
ge
n
in
SS
SF
[2
4–
26
]
In
vi
vo
10
∼
40
m
g/
L
Re
du
ct
io
n
of
PS
vo
lu
m
e
40
∼
12
0m
g/
L
A
nt
ip
ro
lif
er
at
io
n
of
SS
SF
Lo
ca
li
nj
ec
tio
n
20
∼
80
m
g/
L
Pr
om
ot
io
n
of
H
PS
ap
op
to
sis
D
ec
re
as
eo
fh
yp
er
tro
ph
ic
in
de
x
Re
du
ct
io
n
of
co
lla
ge
n
fib
er
co
nt
en
t
O
xy
m
at
rin
e
So
ph
or
a
ja
po
ni
ca
Le
gu
m
in
os
ae
Ro
ot
In
vi
tro
0.
12
5∼
1.0
m
g/
m
L
2𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
KF
b
an
d
H
Fb
Pr
om
ot
io
n
of
KF
b
ap
op
to
sis
In
cr
ea
se
of
S
ph
as
e,
in
hi
bi
to
ry
m
RN
A
ex
pr
es
sio
n
of
co
lla
ge
n
I/c
ol
la
ge
n
II
Ia
nd
re
du
ct
io
n
of
pr
ot
ei
n
ex
pr
es
sio
n
of
Sm
ad
3
an
d
ER
K 1
Pr
om
ot
io
n
of
Sm
ad
7
pr
ot
ei
n
ex
pr
es
sio
n
In
hi
bi
tio
n
of
p-
Sm
ad
3
an
d
nu
cle
ar
tr
an
slo
ca
tio
n
of
Sm
ad
3
[2
7,
28
]
G
in
se
no
sid
e
Rg
3
(G
-R
g3
)
Pa
na
x
gi
ns
en
g
A
ra
lia
ce
ae
Ro
ot
,
rh
iz
om
e
In
vi
vo
Lo
ca
li
nj
ec
tio
n
3m
g/
m
L,
0.
1m
L
In
hi
bi
tio
n
of
H
S
D
ec
re
as
eo
fs
ca
rt
iss
ue
fib
ro
sis
In
cr
ea
se
of
pr
ot
ei
n
ex
pr
es
sio
n
of
PC
N
A
,
Ba
x,
ca
sp
as
e-
3,
an
d
Cy
t-c
D
ec
re
as
eo
f
Bc
l-2
pr
ot
ei
n
ex
pr
es
sio
n
[2
9,
30
]
O
sth
ol
e
Cn
id
iu
m
m
on
ni
er
i
Ap
ia
ce
ae
Fr
ui
t
In
vi
tro
5∼
50
𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
an
d
In
du
ct
io
n
of
ap
op
to
sis
Pr
om
ot
io
n
of
Ba
x
m
RN
A
ex
pr
es
sio
n
an
d
in
hi
bi
tio
n
of
Bc
l-2
m
RN
A
ex
pr
es
sio
n
D
ec
re
as
es
of
TG
F-
𝛽
1
pr
ot
ei
n
ex
pr
es
sio
n
an
d
fa
ci
lit
at
io
n
of
H
SF
Bs
sh
rin
ka
ge
,
ch
ro
m
at
in
co
nd
en
sa
tio
n,
m
em
br
an
e
bl
eb
bi
ng
,a
po
pt
ot
ic
bo
dy
fo
rm
at
io
n,
an
d
D
N
A
la
dd
er
fo
rm
at
io
n
[3
1]
6 Evidence-Based Complementary and Alternative Medicine
Ta
bl
e
2:
A
nt
ih
yp
er
tro
ph
ic
sc
ar
di
sp
lay
in
g
ph
yt
oc
he
m
ic
al
sw
id
ely
di
st
rib
ut
ed
in
m
ed
ic
in
al
pl
an
ts.
Ph
yt
oc
he
m
ic
al
s
O
bs
er
va
tio
n
D
os
e
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
10
-
H
yd
ro
xy
ca
m
pt
ot
he
ci
n
(H
CP
T)
In
vi
vo
0.
01
∼
0.
1m
g/
m
L
D
ec
re
as
eo
ft
he
ar
ea
of
ep
id
ur
al
sc
ar
tis
su
ea
nd
th
e
nu
m
be
ro
ffi
br
ob
la
sts
.R
ed
uc
tio
n
of
ep
id
ur
al
ad
he
sio
n
an
d
in
hi
bi
to
ry
pr
ol
ife
ra
tio
n
of
RE
SF
In
hi
bi
tio
n
of
to
po
iso
m
er
as
eI
[5
]
A
ng
eli
ca
na
ph
th
a
In
vi
tro
1∼
16
m
g/
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
an
d
in
du
ct
io
n
of
H
SF
Bs
ap
op
to
sis
In
hi
bi
tio
n
of
G
0/
G
1
an
d
G
2/
M
ph
as
es
,
pr
om
ot
io
n
of
S
ph
as
e,
an
d
re
du
ct
io
n
of
co
lla
ge
n
pr
ot
ei
n
in
fib
ro
bl
as
ts
[3
2]
As
ia
tic
os
id
e
In
vi
vo
In
vi
tro
25
∼
50
m
g/
m
L
Lo
ca
li
nj
ec
tio
n
25
∼
10
00
𝜇
M
30
0𝜇
g/
m
L
Re
du
ct
io
n
of
sc
ar
hy
pe
rp
la
sia
of
H
SR
E
D
ec
re
as
eo
fh
yp
er
tro
ph
ic
in
de
x
Pr
om
ot
io
n
of
ke
ra
tin
oc
yt
es
m
ig
ra
tio
n
A
nt
i-p
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
th
em
RN
A
ex
pr
es
sio
n
of
TG
F-
𝛽
1,
Rh
oc
A
,R
O
CK
-I
,a
nd
CT
G
F,
fa
ci
lit
at
io
n
of
TG
F-
𝛽
3
m
RN
A
ex
pr
es
sio
n,
an
d
de
cr
ea
se
of
th
ee
xp
re
ss
io
n
of
ty
pe
sI
/II
I
co
lla
ge
n
an
d
TI
M
P-
1p
ro
te
in
s
[3
3–
36
]
M
at
rin
e
In
vi
tro
0.
01
∼
5.
00
g/
L
A
nt
ip
ro
lif
er
at
io
n
an
d
in
du
ct
io
n
of
ap
op
to
sis
in
H
SF
Bs
Pr
om
ot
io
n
of
G
2-
M
ph
as
e,
in
hi
bi
tio
n
of
la
ct
at
ed
eh
yd
ro
ge
na
se
an
d
H
yp
an
d
en
ha
nc
em
en
to
fI
/II
Ic
ol
la
ge
n
ra
tio
[3
7]
Q
ue
rc
et
in
In
vi
vo
0.
05
%
∼
1%
,w
/o
Lo
ca
lA
pp
lic
at
io
n
In
hi
bi
tio
n
of
sc
ar
rin
g
in
ha
irl
es
sm
ic
e
In
cr
ea
se
of
th
ep
ro
te
in
an
d
m
RN
A
ex
pr
es
sio
n
of
M
M
P-
1a
nd
en
ha
nc
em
en
to
f
th
ep
ho
sp
ho
ry
la
tio
n
of
JN
K
an
d
ER
K
[3
8]
In
vi
tro
10
∼
40
𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
Sk
F
Em
od
in
In
vi
tro
50
∼
20
0𝜇
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
G
0/
G
1
ph
as
e,
in
cr
ea
se
of
in
tr
ac
el
lu
la
rc
al
ci
um
,a
nd
de
cr
ea
se
of
co
lla
ge
n
sy
nt
he
sis
[3
9–
41
]
Re
sv
er
at
ro
l
In
vi
tro
In
vi
vo
25
∼
40
0𝜇
M
15
0∼
40
0𝜇
M
Lo
ca
li
nj
ec
tio
ns
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
Re
du
ct
io
n
of
hy
pe
rt
ro
ph
ic
sc
ar
in
de
x
In
hi
bi
tio
n
of
th
em
RN
A
ex
pr
es
sio
n
of
ty
pe
I/t
yp
eI
II
pr
oc
ol
la
ge
ns
[4
2]
Ta
n
IIA
In
vi
tro
20
∼
80
𝜇
g/
m
L
0.
05
∼
0.
15
m
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
du
ct
io
n
of
H
SF
Bs
ap
op
to
sis
Fa
ci
lit
at
io
n
of
nu
cle
is
hr
in
ka
ge
,
co
nd
en
sa
tio
n
an
d
fr
ag
m
en
ta
tio
n,
bl
oc
ka
ge
of
H
SF
Bs
fro
m
G
1
to
S
ph
as
es
,
do
w
nr
eg
ul
at
io
n
of
M
D
A
co
nt
en
ta
nd
XO
D
ac
tiv
ity
,i
nc
re
as
eo
fT
-S
O
D
an
d
G
SH
-P
x
ac
tiv
ity
,a
nd
pr
om
ot
io
n
of
M
M
P-
1m
RN
A
ex
pr
es
sio
n
[4
3–
45
]
Cu
rc
um
in
In
vi
tro
12
.5
∼
10
0𝜇
M
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
pr
oc
ol
la
ge
n
1m
RN
A
ex
pr
es
sio
n
Re
du
ct
io
n
of
hy
pe
rt
ro
ph
ic
in
de
x
an
d
co
lla
ge
n
fib
er
ar
ea
de
ns
ity
[4
6]
In
vi
vo
0.
5∼
2.
0m
M
,0
.1
m
L/
d
Lo
ca
l
in
je
ct
io
ns
D
ih
yd
ro
ar
te
m
isi
ni
n
In
vi
vo
18
0m
g/
kg
In
hi
bi
tio
n
of
H
SR
E
sc
ar
rin
g
In
hi
bi
tio
n
of
co
lla
ge
n
fib
er
sa
nd
hy
pe
rt
ro
ph
ic
in
de
x
[4
7]
10
m
L
in
tr
ag
as
tr
ic
ad
m
in
ist
ra
tio
n
A
nt
ifi
br
ob
la
st
pr
ol
ife
ra
tio
n
of
H
SR
E
A
rt
ea
nn
ui
n
In
vi
tro
0.
10
3∼
0.
20
6m
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
C
on
gr
eg
at
io
n
of
nu
cle
ar
ch
ro
m
at
in
,
pr
om
ot
io
n
of
ca
lc
iu
m
co
nc
en
tr
at
io
n,
in
cr
ea
se
of
G
0-
G
1
ph
as
e,
an
d
re
du
ct
io
n
of
co
lla
ge
n
le
ve
ls
an
d
hy
pe
rt
ro
ph
ic
in
de
x
of
H
SR
E
[4
8–
51
]
In
vi
vo
60
m
g/
m
L/
2d
D
ec
re
as
eo
fH
SR
E
sc
ar
rin
g
20
𝜇
L
lo
ca
li
nj
ec
tio
n
A
nt
ip
ro
lif
er
at
io
n
of
m
as
to
cy
te
Evidence-Based Complementary and Alternative Medicine 7
Ta
bl
e
2:
C
on
tin
ue
d.
Ph
yt
oc
he
m
ic
al
s
O
bs
er
va
tio
n
D
os
e
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
Pa
na
x
no
to
gi
ns
en
g
sa
po
ni
ns
(P
N
S)
In
vi
tro
40
0∼
80
0𝜇
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
G
2-
M
an
d
G
0-
G
1
ph
as
es
,
in
cr
ea
se
of
S
ph
as
e,
re
du
ct
io
n
of
th
ep
ro
te
in
ex
pr
es
sio
n
of
TG
F-
𝛽
1
an
d
𝛼
-S
M
A
,a
nd
in
hi
bi
tio
n
of
in
tr
ac
el
lu
la
rf
re
ec
al
ci
um
co
nc
en
tr
at
io
n
[5
2,
53
]
O
le
an
ol
ic
Ac
id
In
vi
vo
To
pi
ca
la
pp
lic
at
io
n
of
2.
5,
5,
an
d1
0%
fo
r2
8
co
ns
ec
ut
iv
e
da
ys
In
hi
bi
tio
n
of
hy
pe
rt
ro
ph
ic
sc
ar
rin
g,
in
du
ct
io
n
of
ap
op
to
sis
,a
nd
re
du
ct
io
n
of
sc
ar
ele
va
tio
n
in
de
x
In
hi
bi
tio
n
of
th
em
RN
A
ex
pr
es
sio
n
of
TG
F-
𝛽
1
m
RN
A
,M
M
P-
1,
TI
M
P-
1,
an
d
P3
11
.
In
cr
ea
se
of
th
em
RN
A
ex
pr
es
sio
n
of
M
M
P-
2,
ca
sp
as
e-
3,
an
d
ca
sp
as
e-
9.
Re
du
ct
io
n
of
th
ep
ro
te
in
ex
pr
es
sio
n
of
TG
F-
𝛽
1
an
d
co
lla
ge
n
I/c
ol
la
ge
n
II
I
[5
4]
H
iru
di
n
In
vi
tro
1∼
50
𝜇
M
Pr
om
ot
io
n
of
ap
op
to
sis
In
cr
ea
se
of
G
l
ph
as
ea
nd
in
hi
bi
tio
n
of
S
ph
as
eE
nh
an
ce
m
en
to
ft
he
pr
ot
ei
n
ex
pr
es
sio
n
of
M
M
P-
2,
M
M
P-
9,
an
d
p2
7,
re
du
ct
io
n
of
th
ep
ro
te
in
ex
pr
es
sio
n
of
cy
cli
n
E
an
d
TG
F-
𝛽
1,
an
d
in
hi
bi
tio
n
of
th
em
RN
A
ex
pr
es
sio
n
of
I/I
II
pr
oc
ol
la
ge
ns
[5
5]
Xi
am
en
m
yc
in
In
vi
vo
10
m
g/
kg
⋅
d−
1 ,
in
tr
ap
er
ito
ne
al
in
je
ct
io
n
fo
r1
0
da
ys
At
te
nu
at
io
n
of
hy
pe
rt
ro
ph
ic
sc
ar
rin
g
an
d
su
pp
re
ss
io
n
of
lo
ca
li
nfl
am
m
at
io
n
in
am
ec
ha
ni
ca
ls
tre
tc
h-
in
du
ce
d
m
ou
se
m
od
e
Re
du
ct
io
n
of
CD
4+
ly
m
ph
oc
yt
ea
nd
m
on
oc
yt
e/
m
ac
ro
ph
ag
er
et
en
tio
n
in
fib
ro
tic
fo
ci
Bl
oc
ka
ge
of
fib
ro
bl
as
ta
dh
es
io
n
w
ith
m
on
oc
yt
es
.
In
ac
tiv
at
io
n
of
FA
K,
p3
8,
an
d
Rh
o
gu
an
os
in
et
rip
ho
sp
ha
ta
se
sig
na
lin
g
[5
6]
In
vi
tro
5–
30
𝜇
g/
m
L
In
hi
bi
tio
n
of
pr
ol
ife
ra
tio
n
of
H
SF
Bs
8 Evidence-Based Complementary and Alternative Medicine
Ta
bl
e
3:
Th
ee
xt
ra
ct
sf
ro
m
m
ed
ic
in
al
pl
an
ts
di
sp
lay
in
g
an
ti-
hy
pe
rt
ro
ph
ic
sc
ar
rin
g.
Ex
tr
ac
t
Bo
ta
ni
ca
ln
am
e
Fa
m
ily
M
ed
ic
in
al
pa
rt
O
bs
er
va
tio
n
D
os
ea
dm
in
ist
ra
tio
n
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
Et
ha
no
lic
ex
tr
ac
t
Ca
lo
tro
pi
s
gi
ga
nt
ea
As
cle
pi
ad
ac
ea
e
Ro
ot
,b
ar
k
In
vi
vo
10
0∼
40
0m
g/
kg
in
tr
ag
as
tr
ic
ad
m
in
ist
ra
tio
n
In
cr
ea
se
of
wo
un
d
co
nt
ra
ct
io
n
an
d
de
cr
ea
se
of
sc
ar
ar
ea
an
d
th
e
tim
eo
fe
pi
th
eli
za
tio
n
In
cr
ea
se
of
hy
dr
ox
yp
ro
lin
ea
nd
co
lla
ge
n
sy
nt
he
sis
[6
]
Et
ha
no
lic
ex
tr
ac
t
D
au
cu
sc
ar
ot
a
Ap
ia
ce
ae
Ro
ot
In
vi
vo
1,
2,
an
d
4%
ep
id
er
m
al
ad
m
in
ist
ra
tio
n
D
ec
re
as
eo
fw
ou
nd
ar
ea
,
ep
ith
eli
za
tio
n
pe
rio
d,
an
d
sc
ar
w
id
th
.I
nc
re
as
eo
fw
ou
nd
co
nt
ra
ct
io
n
In
cr
ea
se
of
hy
dr
ox
yp
ro
lin
ec
on
te
nt
.
A
nt
io
xi
da
nt
an
d
an
tim
ic
ro
bi
al
ac
tiv
iti
es
[7
]
M
et
ha
no
lic
ex
tr
ac
t
Pi
sti
a
str
at
io
te
s
A
ra
ce
ae
Le
av
e
In
vi
vo
5
an
d
10
%
ep
id
er
m
al
ad
m
in
ist
ra
tio
n
D
ec
re
as
eo
fw
ou
nd
ar
ea
In
hi
bi
tio
n
of
hy
dr
ox
yl
ra
di
ca
l
sc
av
en
gi
ng
an
d
in
cr
ea
se
of
fib
ro
bl
as
tb
lo
od
ve
ss
els
an
d
co
lla
ge
n
fib
er
s
[8
]
Et
hy
la
ce
ta
te
ex
tr
ac
t
G
eli
di
um
am
an
sii
G
eli
di
ac
ea
e
W
ho
le
pl
an
t
In
vi
tro
5∼
10
m
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
D
ec
re
as
eo
ft
he
pr
ot
ei
n
ex
pr
es
sio
n
of
I/I
II
co
lla
ge
ns
an
d
TG
F-
𝛽
1
[9
]
Et
ha
no
lic
ex
tr
ac
t
Ca
rt
ha
m
us
tin
ct
or
iu
s
As
te
ra
ce
ae
Fl
ow
er
In
vi
tro
2∼
8𝜇
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
hi
bi
tio
n
of
co
lla
ge
n
pr
ot
ei
n
sy
nt
he
sis
an
d
pr
om
ot
io
n
of
fib
ro
bl
as
ts
hr
in
ka
ge
[5
7]
Aq
ue
ou
s
ex
tr
ac
t
O
en
ot
he
ra
pa
ra
do
xa
O
na
gr
ac
ea
e
Se
ed
In
vi
tro
0.
1∼
10
𝜇
g/
m
L
Pr
ot
ec
tio
n
of
no
rm
al
de
rm
al
fib
ro
bl
as
ts
D
ec
re
as
eo
fL
D
H
an
d
RO
S
[5
8]
Aq
ue
ou
s
ex
tr
ac
t
Ci
ga
re
tte
Sm
ok
e
U
nk
no
w
n
U
nk
no
w
n
In
vi
tro
10
0%
sa
tu
ra
te
d
so
lu
tio
n
A
nt
ip
ro
lif
er
at
io
n
of
sk
in
fib
ro
bl
as
ts
an
d
pr
om
ot
io
n
of
ce
llu
la
rs
en
es
ce
nc
e
In
hi
bi
tio
n
of
SO
D
an
d
G
SH
-P
x
an
d
pr
om
ot
io
n
of
RO
S
[5
9]
Et
hy
la
ce
ta
te
ex
tr
ac
t
Rh
eu
m
pa
lm
at
um
Po
ly
go
na
ce
ae
Ro
ot
,
rh
iz
om
e
In
vi
tro
25
𝜇
g/
m
L
A
nt
ip
ro
lif
er
at
io
n
of
H
SF
Bs
In
cr
ea
se
of
G
0/
G
1
ph
as
e
[6
0]
M
et
ha
no
l
ex
tr
ac
t
Br
ou
sso
ne
tia
ka
zin
ok
i
M
or
ac
ea
e
Ba
rk
,r
oo
t
In
vi
tro
U
nk
no
w
n
In
hi
bi
tio
n
of
hy
pe
rp
ig
m
en
ta
tio
n
Re
du
ct
io
n
of
ty
ro
sin
as
ee
nz
ym
e
sy
nt
he
sis
[6
1]
Et
ha
no
l
ex
tr
ac
t
Sc
ut
ell
ar
ia
ba
ica
len
sis
G
eo
rg
i
La
m
ia
ce
ae
Ro
ot
In
vi
vo
10
m
g/
m
L
ep
id
er
m
al
ad
m
in
ist
ra
tio
n
In
hi
bi
tio
n
of
sc
ar
rin
g
Re
du
ct
io
n
of
th
ep
ro
te
in
ex
pr
es
sio
n
of
TG
F-
𝛽
1
[6
2]
Aq
ue
ou
s
ex
tr
ac
t
Al
liu
m
ce
pa
Li
lia
ce
ae
C
or
m
In
vi
vo
1∼
2.
5%
,v
/v
lo
ca
la
pp
lic
at
io
n
Su
pp
re
ss
io
n
of
sc
ar
rin
g
in
ha
irl
es
sm
ic
e
U
pr
eg
ul
at
io
n
of
M
M
P-
1a
nd
ty
pe
I
co
lla
ge
n
ex
pr
es
sio
n
[3
8]
In
vi
tro
1∼
2.
5%
,v
/v
A
nt
ip
ro
lif
er
at
io
n
of
fib
ro
bl
as
ts
Aq
ue
ou
s
ex
tr
ac
t
Ta
m
ar
in
du
s
in
di
ca
Fa
ba
ce
ae
Ba
rk
,l
ea
ve
In
vi
vo
U
nk
no
w
n
A
nt
i-i
nfl
am
m
at
io
n
El
im
in
at
io
n
of
de
at
h
ce
lls
an
d
ne
cr
ot
ic
tis
su
es
[6
3]
Et
ha
no
l
ex
tr
ac
t
An
eil
em
a
ke
isa
k
C
om
m
el
in
ac
ea
e
W
ho
le
pl
an
t
In
vi
tro
40
𝜇
g/
m
L
D
ec
re
as
eo
fs
ca
rr
in
g
In
hi
bi
tio
n
of
TG
F-
𝛽
1-d
ep
en
de
nt
sig
na
lli
ng
by
re
du
ci
ng
Sm
ad
2
pr
ot
ei
n.
Re
du
ct
io
n
of
va
rio
us
hK
F
pa
th
ol
og
ic
al
re
sp
on
se
s,
in
clu
di
ng
hy
pe
rp
la
st
ic
gr
ow
th
,c
ol
la
ge
n
pr
od
uc
tio
n,
an
d
m
ig
ra
tio
n
w
ith
ou
t
D
N
A
da
m
ag
e
[6
4]
Evidence-Based Complementary and Alternative Medicine 9
Ta
bl
e
4:
Th
ep
re
pa
ra
tio
ns
fro
m
di
ffe
re
nt
m
ed
ic
in
al
pl
an
ts
w
ith
an
tih
yp
er
tro
ph
ic
sc
ar
ac
tiv
ity
.
Pr
ep
ar
at
io
ns
Bo
ta
ni
ca
ln
am
e
Fa
m
ily
M
ed
ic
in
al
pa
rt
Pr
ep
ar
at
io
n
Ve
hi
cle
D
eli
ve
ry
sy
ste
m
O
bs
er
va
tio
n
Eff
ec
t
M
ec
ha
ni
sm
of
ac
tio
n
Re
fe
re
nc
es
H
yd
ro
xy
ca
m
pt
ot
he
ci
n
(H
CP
T)
Ca
m
pt
ot
he
ca
ac
um
in
at
a
N
ys
sa
ce
ae
Fr
ui
t,
le
av
e
Li
po
so
m
e-
en
ca
ps
ul
at
ed
10
-H
CP
T
Li
po
so
m
e
Li
po
so
m
e-
en
ca
ps
ul
at
ed
In
vi
vo
Im
pl
an
t
A
nt
ip
ro
lif
er
at
io
n
of
fib
ro
bl
as
ts
an
d
re
du
ct
io
n
of
ep
id
ur
al
ad
he
sio
n
D
ec
re
as
eo
fe
pi
du
ra
ls
ca
ra
re
a
an
d
fib
ro
bl
as
tn
um
be
ri
n
th
e
ep
id
ur
al
sc
ar
tis
su
e
[6
5,
66
]
O
xy
m
at
rin
e(
O
M
T)
So
ph
or
a
fla
ve
sc
en
s,
So
ph
or
a
al
op
ec
ur
oi
de
s,
an
d
So
ph
or
a
su
bp
ro
str
at
a
Le
gu
m
in
os
ae
U
nk
no
w
n
O
xy
m
at
rin
e-
ph
os
ph
ol
ip
id
co
m
pl
ex
(O
M
T-
PL
C)
Ph
os
ph
ol
ip
id
M
ic
ro
em
ul
sio
n
In
vi
tro
In
vi
vo
to
pi
ca
l
de
liv
er
y
A
nt
ip
ro
lif
er
at
io
n
of
fib
ro
bl
as
ts
Im
pr
ov
em
en
to
fO
M
T
sk
in
pe
rm
ea
bi
lit
y
an
d
in
cr
ea
se
of
re
te
nt
io
n
ra
tio
of
O
M
T
in
sk
in
.
[6
7]
A
str
ag
al
os
id
eI
V
As
tra
ga
lu
s
m
em
br
an
ac
eu
s
Le
gu
m
in
os
ae
Ro
ot
So
lid
lip
id
na
no
pa
rt
ic
le
-
en
ric
he
d
hy
dr
og
el
(S
LN
-g
el
)
Li
pi
d
hy
dr
og
el
So
lid
lip
id
na
no
pa
rt
ic
le,
hy
dr
og
el
In
vi
tro
In
vi
vo
,
to
pi
ca
l
de
liv
er
y
En
ha
nc
em
en
to
f
ke
ra
tin
oc
yt
es
m
ig
ra
tio
n
an
d
pr
ol
ife
ra
tio
n
In
cr
ea
se
of
dr
ug
up
ta
ke
in
fib
ro
bl
as
ts
Pr
om
ot
io
n
of
w
ou
nd
he
al
in
g
an
d
in
hi
bi
tio
n
of
sc
ar
fo
rm
at
io
n
Ca
ve
ol
ae
en
do
cy
to
sis
pa
th
w
ay
.
In
cr
ea
se
of
w
ou
nd
clo
su
re
ra
te
an
d
an
gi
og
en
es
is
Im
pr
ov
em
en
t
of
co
lla
ge
n
re
gu
la
r
or
ga
ni
za
tio
n
[6
8]
G
in
se
no
sid
eR
g3
(G
-R
g3
)
Re
dP
an
ax
gi
ns
en
g
A
ra
lia
ce
ae
Ro
ot
,
rh
iz
om
e
G
in
se
no
sid
e
Rg
3/
Po
ly
(l-
la
ct
id
e)
(G
-R
g3
/P
LL
A
)
El
ec
tro
sp
un
po
ly
(L
-la
ct
id
e)
fib
er
El
ec
tro
sp
un
fib
ro
us
sc
aff
ol
ds
,
na
no
fib
er
s
In
vi
tro
In
vi
vo
In
hi
bi
tio
n
of
fib
ro
bl
as
t
ce
ll
gr
ow
th
,
an
tip
ro
lif
er
at
io
n
of
fib
ro
bl
as
ts,
an
d
pr
ev
en
tio
n
of
sc
ar
fo
rm
at
io
n
Im
pr
ov
em
en
to
fd
er
m
is
la
ye
r
th
ic
kn
es
s,
co
lla
ge
n
fib
er
s,
an
d
m
ic
ro
ve
ss
els
[2
9]
C
en
te
lla
as
ia
tic
ae
xt
ra
ct
Ce
nt
ell
a
as
ia
tic
a
Ap
ia
ce
ae
W
ho
le
pl
an
t
Ce
nt
ell
a
as
ia
tic
a
ex
tr
ac
t
ca
ps
ul
e
Ca
ps
ul
e
N
ot
hi
ng
In
vi
vo
In
hi
bi
tio
n
of
tis
su
e
ov
er
gr
ow
th
,r
ed
uc
tio
n
of
sc
ar
an
d
ke
lo
id
,a
nd
an
ti-
in
fla
m
m
at
io
n
Pr
om
ot
io
n
of
co
lla
ge
n
I
pr
ot
ei
n
ex
pr
es
sio
n,
co
lla
ge
n
re
m
od
eli
ng
,a
nd
gl
yc
os
am
in
og
ly
ca
n
sy
nt
he
sis
En
ha
nc
em
en
to
fc
ol
la
ge
n
an
d
ac
id
ic
m
uc
op
ol
ys
ac
ch
ar
id
es
[6
9]
10 Evidence-Based Complementary and Alternative Medicine
Table 5: Summary of antiscarring mechanisms of medicinal plant components.
Mechanism Medicinal plant component
MAPK pathway
Inhibition of p-p38 signaling Madecassoside, Genistein, and Xiamenmycin
Inhibition of p-ERK1/2 signaling Genistein, Tetrandrine, Cryptotanshinone, andQuercetin
Inhibition of p-JNK signaling Quercetin
PI3K/AKT signaling Madecassoside
Mitochondrial-dependent
pathway
Increase of Bax Madecassoside, Genistein, Ginsenoside Rg3, andOsthole
Decrease of Bcl-2 Madecassoside, Genistein, Tetrandrine, GinsenosideRg3, and Osthole
Increase of cytoplasm Cyt-c Ginsenoside Rg3
Cell cycle
Decrease of G0-G1 phase
Genistein, Angelica naphtha, Emodin, and Panax
notoginseng saponins
Increase of G2-M Genistein
Decrease of S phase 10-Hydroxycamptothecin, Tetrandrine, Aloe emodin,and Hirudin
Prevention from G0/G1 into G2 phase Tetrandrine
RhoA/ROCK-I signal pathway Inhibitory secretion of RhocA, ROCK-I, andCTGF Xiamenmycin
VEGF signal pathway Cryptotanshinone
FAK signal pathway Cryptotanshinone, Xiamenmycin
TGF-𝛽/Smad signaling pathway Oxymatrine
Downregulation of collagen I/III
expression
Genistein, Astragaloside IV, Tetrandrine, Resveratrol,
5F, Curcumin, Oleanolic Acid, and Hirudin
Decrease of 𝛼-SMA Genistein, Panax notoginseng saponins
Activation of caspases Activation of caspase-3
Madecassoside, Genistein, 5F, Cryptotanshinone,
Oleanolic Acid, and Ginsenoside Rg3
Activation of caspase-9 Madecassoside, Oleanolic Acid
Suppression of TPK activation Kazinol F
Inhibition of topoisomerase I 10-Hydroxycamptothecin
Decrease of TGF-𝛽1 secretion
Tetrandrine, Panax notoginseng saponins, Osthole, and
Hirudin
Inhibition of TGF-𝛽1
transcription Astragaloside IV, Oleanolic Acid
Downregulation of TIMP-l
expression Oleanolic Acid
Reduction of LDH and increase
of the ratio of collagen I/collagen
III
Matrine
Increase of T-SOD and GSH-Px
activity Tan IIA
MMP
Enhancement of MMP-1 Tetrandrine, Tan IIA, and Oleanolic Acid
Enhancement of MMP-2 and MMP-9 Hirudin
Enhancement of MMP-13 Madecassoside
Increase of intracellular calcium Emodin, Arteannuin
poor absorption, and biotransformation or compact scar
tissue. The appropriate form of prepared drugs can evidently
improve drug permeability, lipid solubility, skin permeability,
retention ratio, release time, and cytotoxicity. Hydroxycamp-
tothecin (HCPT) is thought to be one of the most effective
components against scars. However, the poor solubility and
short half-life severely limit its clinical applications [65].
Compared with HCPT, the liposome-encapsulated HCPT
(L-HCPT) can reduce epidural fibrosis by preventing the
proliferation of fibroblasts in the scar tissue with longer half-
life and better solubility [65]. The application of a silicone
derivative to herbal extracts can improve skin pliability and
alleviate the concomitant symptoms of scars including pain
and itching [2]. However, it is extremely important to control
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Table 6: Summary of antiscarring mechanisms of plant extracts.
Mechanism Medicinal plants extract
Cell cycle
Increase of G0-G1 phase Rhubarb
Collagen
Downregulation of collagen l expression Gelidium amansii
Downregulation of collagen III expression Gelidium amansii, Scutellaria baicalensis Georgi
Enhancement of collagen synthesis Calotropis gigantea
Inhibition of collagen synthesis Carthamus tinctorius
Promotion of collagen I Onion
MMP
Enhancement of MMP-1 Neonauclea reticulata, Onion
Increase of MMP-3 and MMP-9 Neonauclea reticulata
Elimination of hydroxyl radical Pistia stratiotes
Decrease of LDH Oenothera paradoxa
Decrease of ROS Oenothera paradoxa, Neonauclea reticulata
Increase of ROS and reduction of SOD and GSH-Px Cigarette Smoke
the cytotoxicity of biomaterials for their clinical applications.
Microemulsion, a transparent dispersion system, is a good
vehicle for drug delivery due to its many advantages such
as thermodynamic stability (long shelf life), easy formation
(zero interfacial tension), low viscosity, high surface area
(high solubilization capacity), and small droplet size [67]. It
has been revealed that drug-free microemulsion is a promis-
ing preparation due to inapparent cytotoxicity [67].The local
or transdermal application of water-soluble pharmaceutical
formulation may be suitable for medicinal plant extracts and
compounds.
Owing to compact scar tissue, it is necessary for the
combination of natural products or crude extracts with some
adjuvant as new dosage forms to increase their solubility,
content, release time, uptake, and penetrability.These dosage
forms include microemulsion [67], liposomes [66], solid
lipid nanoparticle [68], and electrospun fibrous scaffolds
[29]. Improvement of drug permeation may be a promising
treatment in future research on the basis of the known
medicinal plants.
In addition, some of these plant extracts or purified
chemical components are prepared as traditional medicinal
injections for the deep antiscar treatment. For example,
Carthamus tinctorius injection, whose primary component
is hydroxysaflor yellow A, softens hypertrophic scar tissue
and inhibits fibroblast proliferation by decreasing the type
I/type III collagens ratio and the TGF-𝛽
1
level after local
treatment [77]. The radix astragali injection also inhibits the
proliferation and reduces scar thickness and hardness by
reducing Smad3 and TGF-𝛽
1
levels [78].
5. Current Treatment and
Prospects for Future Therapies
Currently, occlusive dressings, compression therapy, intrale-
sional steroid, cryosurgery, laser, radiation, surgical excision,
and interferon therapy are curative for themajority of patients
with hypertrophic scars [79]. Surgical therapy and excising
fiber fraction are the common approaches for the treatment
of hypertrophic scars. However, significant disadvantages
were reported, such as the recurrence of adhesion after
surgery as high as 45%–100% [54], which seriously limits its
extensive application to scar prevention. Accordingly, physio-
therapy is established, including occlusive dressings, pressure
therapy, cryosurgery, radiation therapy, and laser therapy.
Meanwhile, pharmacotherapy is also frequently applied,
such as intralesional corticosteroid injection and topical
drug treatment with interferon, bleomycin, 5-fluorouracil,
verapamil, vitamin E, imiquimod, TGF-𝛽
3
, or interleukin-
10 [79, 80]. Pharmacotherapy mainly inhibits inflammation,
proliferation, and remodeling phase [7] or modifies ECM
metabolism via interfering the pivotal molecules of MAPK,
TGF-𝛽, and PI3K signaling transduction.
However, there is no ideal treatment for hypertrophic
scars so far and some chemical drugs also cause mal-
effects simultaneously. Many kinds of natural products from
medicinal plants have good antiscar activity and shownotable
advantages due to their fewer side-effects. Therefore, in addi-
tion to widespread uses of surgical therapy, physiotherapy,
and pharmacotherapy, there is a great need for developing
new natural drugs more efficient than or synergizing with
the existing ones. Many kinds of purified natural products
originated frommedicinal plants are abundant in the natural
environment, such as Ginsenoside Rg3 [29], Oleanolic Acid
[54], Resveratrol [42], Asiaticoside [34], and Genistein [13],
and are popular as antiscar agents due to their easy obtain-
ment and fewer side-effects. Hence, we overviewed the major
current herbs and their preparations applied to the treatment
of hypertrophic scars.
It is a challenge to identify and evaluate a safe, wholesome,
and effective natural product against scars. Even though a
number of new products have been reported by pharmaco-
logical tests in the last decades,many others remain unknown
or untested.
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6. Discussion
In this review, we gathered publications on medicinal plants
with antihypertrophic scar activity and addressed the ques-
tion whether the treatment of scars with medicinal plants is
effective in humans. Although in vivo and in vitro investiga-
tions play an important role in the evaluation of safety and
effectiveness of medicinal plants in preclinical trials, there is
no perfect denouncement for their ultimate success as human
drugs. Clearly, animal data are not sufficient for the confirma-
tion of the safety and efficacy of medicinal plants in humans
owing to their physiological structure differences. Further-
more, there are some conflicting clinical trials reported. For
example, it has been reported that honey was effective in
rapidly cleaning infection and promoting wound healing,
indicating that honey possessed anti-infection activity [81].
However, it was also reported that honey did not affect the
wound, scar, length, and remained length [82].Therefore, the
effectiveness of some drugs needs to be further clarified.
On the other hand, only four publications reported nega-
tive results in our retried papers. Genistein phosphorylated c-
Raf, MEK1/2, ERK1/2, and p38 proteins, but not JNK protein
[14]. Asiaticoside had no effect on the expression of Smad2,
Smad3, and Smad4 [34], while madecassoside regulated
keloid-derived fibroblasts proliferation, migration, F-actin
filaments, cytoskeletal protein actin, and the phosphorylation
of cofilin via p38 MAPK and PI3K/AKT signaling, but not
ERK1/2 and caspase-8 signaling [12]. Quercetin promoted
phosphorylation of JNK and ERK, but not p38; it increased
the protein and mRNA expression of MMP-1, but not type
I collagen and TIMP-1 [38]. These studies indicate that the
antiscar activity of medicinal plants needs to be scrutinized
further.
Many traditional medicines used in folk medicine are
reported to have antiscar activity, but only a few have been
studied systematically in vitro or/and in vivo, such as rhubarb
[60] and tamarind [63]. Although numerous in vitro studies
have substantiated the antiscar activity of plant extracts and
phytochemicals, there is very little evidence in humans. The
number of clinical trials and their highlighted results are
limited. The numerous traditional formulations effectively
and extensively used in clinics have not been investigated.
Also, the majority of the plants (Tables 1, 2, and 3) tradi-
tionally used as antiscar agents have not been investigated
in animals. The phytochemicals with in vitro antiscar activity
may have no effects in vivo due to the exceedingly high doses.
Moreover,many of these phytochemicals have not been tested
for their cytotoxicity, acute toxicity, or/and long-term toxicity
in normal cells and animals, which seriously limits in vivo
investigations. Only twomedicinal plants have been reported
on their untoward reactions and cytotoxic effects.The clinical
efficacy and safety should be investigated simultaneously for
medicinal plant extracts and compounds.
The natural barrier of skin can block drug getting through
stratum corneum or decrease the amount of drug perme-
ation, causing inefficiency or low-efficiency of drugs. Some
adjuvants can significantly improve the penetrability of drugs
and the desired therapeutic effects can be achieved. For
example, hydroxycamptothecin (HCPT) is considered one
of the most effective agents against scars, which prevents
fibroblast proliferation and reduces epidural adhesion, but
the poor solubility and short half-life severely limits its clini-
cal application [65]. Somenewdosage forms evidently reverse
these conditions, such as microemulsion [67], liposomes
[66], solid lipid nanoparticle [68], and electrospun fibrous
scaffolds [29]. Therefore, the development of new dose types
is necessary in order to ameliorate drug effects.
Although enormous progress has been achieved over the
last years, the impact of medicinal plants on individual types
of scars needs to be explored in more detail. Polymechanistic
phytochemicals such as Genistein may have an advantage
over targeted therapeutics, which simultaneously tackle scar
treatment from multiple angles. Genistein can act on many
target points, including suppression of PDGF-promoted TPK
activation, decrease of types I/III precollagen and PCNA
expression, reduction of c-Raf, MEK1/2, ERK1/2, and p38
protein phosphorylation, and inhibition of RTK-Ras-MAPK
(ERK/p38) [13]. Further insights into the molecular mech-
anisms of phytochemicals will facilitate the development of
new drugs for the prevention and treatment of human scars.
7. Conclusion
In conclusion, the scaring process is complicated. The char-
acteristics of an appropriate therapy for the prevention and
treatment of scars should comprise the following: simple
and easy delivery, comparability (effectiveness) with current
therapies, and minimal drug interaction with concomitant
treatments and lack of significant side effects [83]. Manyex-
tracts and compounds from medicinal plants can inhibit
scarring. The main mechanisms are suppression of prolif-
eration and/or induction of apoptosis in scar fibroblasts by
regulation of several pathways, such as MAPK, PI3K/AKT,
RhoA/ROCK-I, VEGF, FAK, andTGF-𝛽/Smad.Although the
approaches described here are quite different and mecha-
nisms are complicated, the utility should be maximized for
medicinal plants as antihypertrophic scar agents. However,
screening is necessary to minimize any potentially harmful
side effects on human skin and health.
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